文献速递外周动脉疾病

慢性肾脏病或终末期肾病患者下肢外周动脉干预结局的系统评价与荟萃分析

Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease.
PubMed 文献 · J Vasc Surg · 2020-09-01

结果显示CKD/ESRD组靶病变血运重建(TLR)、大截肢和长期死亡率均显著更高;TLR升高仅见于血管内干预,而大截肢和长期死亡率升高与干预类型无关。

要点

  • CKD/ESRD患者下肢PAD干预后TLR风险更高(OR 1.68),但仅见于血管内干预。
  • CKD/ESRD患者大截肢(OR 1.97)和长期死亡率(OR 2.28)均显著升高。
  • 大截肢和长期死亡率的升高与干预类型(血管内或开放手术)无关。

核心结论

  • 合并CKD/ESRD的下肢PAD干预患者结局劣于肾功能正常者。
  • TLR升高仅见于血管内干预而非开放手术。
  • 大截肢和全因死亡率升高与干预指征无关。

研究设计与样本

  • 系统评价与荟萃分析,检索5个数据库2000年1月至2019年6月。
  • 比较CKD/ESRD与肾功能正常者下肢PAD干预结局,按干预类型分层。
  • 采用随机效应模型合并OR及95%CI,最长随访114个月(范围0.5-114个月)。

主要发现

  • CKD/ESRD组TLR发生率高于肾功能正常组(OR 1.68;95%CI 1.25-2.27;P=.001)。
  • CKD/ESRD组大截肢发生率更高(OR 1.97;95%CI 1.37-2.83;P<.001)。
  • CKD/ESRD组长期死亡率更高(OR 2.28;95%CI 1.45-3.58;P<.001)。
  • TLR升高仅见于血管内干预,开放手术无差异。
  • 大截肢和长期死亡率差异无论干预类型均有统计学意义。

临床怎么用

  • 对CKD/ESRD患者行下肢PAD干预时应充分告知TLR、大截肢和死亡风险升高。
  • 选择血管内干预时需特别关注TLR风险增加。
  • 需针对该高危人群制定循证管理策略。

局限性

  • 纳入研究均为观察性研究,除两项外均采用多变量回归或病例对照匹配控制混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with chronic kidney disease (CKD) have a greater risk of peripheral arterial disease (PAD). Although individual studies have documented an association between CKD and/or end-stage renal disease (ESRD) and adverse outcomes in patients undergoing PAD interventions in an era of technological advances in peripheral revascularization, the magnitude of the effect size is unknown. Therefore, we performed a meta-analysis to compare the outcomes of PAD interventions for patients with CKD/ESRD with those patients with normal renal function, stratified by intervention type (endovascular vs surgical), reflecting contemporary practice. METHODS: Five databases were analyzed from January 2000 to June 2019 for studies that had compared the outcomes of lower extremity PAD interventions for patients with CKD/ESRD vs normal renal function. We included both endovascular and open interventions, with an indication of either claudication or critical limb ischemia. We analyzed the pooled odds ratios (ORs) across studies with 95% confidence intervals (CIs) using a random effects model. Funnel plot and exclusion sensitivity analyses were used for bias assessment. RESULTS: Seventeen observational studies with 13,140 patients were included. All included studies, except for two, had accounted for unmeasured confounding using either multivariable regression analysis or case-control matching. The maximum follow-up period was 114 months (range, 0.5-114 months). The incidence of target lesion revascularization (TLR) was greater in those with CKD/ESRD than in those with normal renal function (OR, 1.68; 95% CI, 1.25-2.27; P = .001). The incidence of major amputations (OR, 1.97; 95% CI, 1.37-2.83; P < .001) and long-term mortality (OR, 2.28; 95% CI, 1.45-3.58; P < .001) was greater in those with CKD/ESRD. The greater TLR rates with CKD/ESRD vs normal renal function were only seen with endovascular interventions, with no differences for surgical interventions. The differences in rates of major amputations and long-term mortality between the CKD/ESRD and normal renal function groups were statistically significant, regardless of the intervention type. CONCLUSIONS: Patients with CKD/ESRD who have undergone lower extremity PAD interventions had worse outcomes than those of patients with normal renal function. When stratifying our results by intervention (endovascular vs open surgery), greater rates of TLR for CKD/ESRD were only seen with endovascular and not with open surgical approaches. Major amputations and all-cause mortality were greater in the CKD/ESRD group, irrespective of the indication. Evidence-based strategies to manage this at-risk population who require PAD interventions are essential.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Anantha-Narayanan M, Sheikh AB, Nagpal S, et al. Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease. J Vasc Surg. 2020. PMID: 32889074. doi:10.1016/j.jvs.2020.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。